Salt and crystal form of egfr inhibitor, and composition and use thereof
US-2024352053-A1 · Oct 24, 2024 · US
2-selenophene-4-quinolones as anticancer agents
US9023866B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9023866-B2 |
| Application number | US-201313892522-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 13, 2013 |
| Priority date | Dec 7, 2006 |
| Publication date | May 5, 2015 |
| Grant date | May 5, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na + form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of 2-selenophene 4-quinolone having the following formulas IIb or IIc: wherein R 2 ′, R 3 ′ and R 4 ′ independently are H, (CH 2 ) n CH 3 , Y(CH 2 ) n CH 3 , or X, wherein n is an integer of 0-4, Y is O, and X is F, Cl, or Br; R 2 and R 5 independently are H, (CH 2 ) n CH 3 , or X, and R 3 and R 4 together is —Y(CH 2 ) n Y—, wherei…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C07F9/6561Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9023866B2 cover?
- 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na + form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A no…
- Who is the assignee on this patent?
- Univ China Medical
- What technology area does this patent fall under?
- Primary CPC classification C07F9/6561. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 05 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).